Clinical trials: insulin glargine
- Drug or intervention insulin glargine
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Type 2 Diabetes Mellitus
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes.
- Trial name
- IMAGINE 8 (NCT02132637)
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 3 sites in United States, Germany
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
- Trial name
- PRONTO-T2D (NCT03214380)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 141 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, Oceania and South America. This trial aims for a comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily all in combination with metformin and…
- Trial name
- NCT00469092
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 69 sites in Argentina, Austria and 13 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
This was a parallel-group treatment, Phase 3, randomized, 2-arm study that assessed the efficacy and safety of iGlarLixi to IDegAsp in Chinese T2DM participants insufficiently controlled with oral antidiabetic drug(s).
- Trial name
- NCT05413369
- Testing
- Insulin glargine/Lixisenatide, IDegAsp, Metformin
- Where
- 60 sites in China
- Volunteers
- 582 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of biphasic insulin aspart 30 once daily compared to insulin glargine once daily both in combination with metformin…
- Trial name
- EasyMix (NCT01123980)
- Testing
- biphasic insulin aspart 30, metformin, glimepiride
- Where
- 34 sites in China, Japan
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
AMI
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and…
- Trial name
- INTENSIVE (NCT00670228)
- Testing
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 34 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes…
- Trial name
- NCT02420262
- Testing
- insulin degludec/liraglutide, insulin glargine, insulin aspart
- Where
- 117 sites in United States, Argentina and 10 more
- Volunteers
- 506 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
- Trial name
- DEVOTE (NCT01959529)
- Testing
- insulin degludec, insulin glargine
- Where
- 446 sites in United States, Algeria and 18 more
- Volunteers
- 7,637 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Type I
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
- Trial name
- NCT00308308
- Testing
- Technosphere Insulin, Active comparator
- Where
- 129 sites in United States, Argentina and 8 more
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
- Trial name
- NCT01027871
- Testing
- LY2605541, insulin glargine
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 289 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus
The purpose of this study is: To assess the efficacy of Nasulin vs. placebo as indicated by time spent in euglycemia, assessed by continuous glucose monitoring data and serum fructosamine levels in patient volunteers with Type 2…
- Trial name
- CPEX-011 (NCT00850096)
- Testing
- Nasulin
- Where
- 21 sites in United States
- Volunteers
- 94 people
- Sponsor
- CPEX Pharmaceuticals Inc.
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes
- Trial name
- NCT00147745
- Testing
- Colesevelam, Insulin glargine (Lantus)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Daiichi Sankyo
Diabetes, Diabetes Mellitus, Type 2
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01135992)
- Testing
- insulin degludec, insulin glargine
- Where
- 27 sites in United States
- Volunteers
- 143 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- BEGIN™ (NCT01079234)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 82 sites in United States, Belgium and 5 more
- Volunteers
- 493 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and North America. The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2…
- Trial name
- BEGIN™ (NCT01068678)
- Testing
- insulin degludec, insulin glargine
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2…
- Trial name
- NCT00560417
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company